Handbook of Therapeutic Antibodies - Dübel, Stefan (ed.)
Marktplatzangebote
Gebraucht bestellen
Ein Angebot für € 200,25 €
  • Gebundenes Buch

In this most comprehensive reference source for the development, production and therapeutic application of antibodies, Volume 1 contains general chapters on the development, production, and therapeutic antibodies as well as providing a look at emerging technologies and future developments. The second volume includes one chapter devoted to each currently approved type of antibody, including the clinical data, as well as overview chapters on those antibodies that are still undergoing clinical trials.
A must-have handbook meeting the needs of both basic and applied research as well as of the…mehr

Produktbeschreibung
In this most comprehensive reference source for the development, production and therapeutic application of antibodies, Volume 1 contains general chapters on the development, production, and therapeutic antibodies as well as providing a look at emerging technologies and future developments. The second volume includes one chapter devoted to each currently approved type of antibody, including the clinical data, as well as overview chapters on those antibodies that are still undergoing clinical trials.
A must-have handbook meeting the needs of both basic and applied research as well as of the pharmaceutical and biotech industries.

Table of contents:
VOLUME I: TECHNOLOGIES
New Therapeutic Concepts
Extraction and Purification
Molecular Engineering
Production
Selection Systems
Clinical Studies
Emerging Technologies
Future Developments of Research and Application
VOLUME II: APPROVED THERAPEUTICS A-M
Abciximab
Adalimumab
Alemtuzumab
Basiliximab
Daclizumab
Gemtuzumab
Infliximab
VOLUME III: APPROVED THERAPEUTICS N-Z, THERAPEUTICS IN CLINICL TRIAL
Omalizumab
Palivizumab
Rituximab
Trastuzumab
Votumumab
Antibodies in Phase I/II for Cancer Therapy
Antibodies in Phase I/II for Infectious Diseases
Antibodies in Phase I/II for Autoimmune Diseases
Autorenporträt
Stefan Dübel got his PhD at the Center for Molecular Biology Heidelberg (ZMBH) and spent his post-doc at the German Cancer Research Center (DKFZ) with research on the development of antibody display libraries. In the following years, he substantially participated in the invention of recombinant antibody phage display technology, as well as other recombinant antibody technologies and the development of various antibody fusion proteins. In 1996, he moved to the University of Heidelberg to establish the antibody engineering group at the Institute of Molecular Genetics. After holding a group leader position at the University of Heidelberg from 1996, Stefan Dübel went to the Biological Faculty of the Technical University of Braunschweig as a full professor in 2002. Here, he currently serves as head of the Department of Biotechnology in Braunschweig and managing director of the Institute of Biochemistry and Biotechnology. He has co-authored more than 90 scientific papers, 17 patents, as well as two acknowledged textbooks in the field of recombinant antibodies. He is also board member of scientific journals and the biotech industry.